Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.

Am Heart J · 2019 · PMC6483973 · PMID 30893577

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

did not reach statistical significanceP = .053so close (0.05 < p ≤ 0.1)

There was a trend towards an improvement in LVEF at follow-up but this did not reach statistical significance (placebo group: 49 ± 8%, MRA group: 54 ± 11%, P = .053).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.